Post hoc analysis of CHANCE-2 (5651 patients, minor stroke or TIA, CYP2C19 loss-of-function alleles): in 1252 with small artery occlusion and nonelevated VCAM-1, 90-day stroke was 2.9% with ticagrelor-aspirin vs 7.5% clopidogrel-aspirin (HR 0.37); mild bleeding was higher.
Secondary analysisn = 5,651
Li et al. Differential Effect of Ticagrelor Versus Clopidogrel by Causative Classification of Stroke Classification and Vascular Cellular Adhesion Molecule-1 Level on the Risk of Recurrent Stroke: A Post Hoc Analysis of the CHANCE-2 Trial